KNSA (STOCKS)
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
$52.340000
+0.450000 (+0.87%)
Prev close: $51.890000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Sanj K. Patel
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $4,031.17M
- Employees
- 315
- P/E (TTM)
- 57.68
- P/B (TTM)
- 6.63
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
5
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$0.27 | $0.21 | +0.0647 | +31.51% |
|
Dec 2025 (Q4)
|
$0.17 | $0.38 | -0.2119 | -55.49% |
|
Sep 2025 (Q3)
|
$0.23 | $0.33 | -0.0998 | -30.26% |
|
Jun 2025 (Q2)
|
$0.23 | $0.19 | +0.0442 | +23.79% |
Financial Statements
| Revenues | $754.05M |
| Benefits Costs and Expenses | $648.06M |
| Cost Of Revenue | $80.60M |
| Costs And Expenses | $648.06M |
| Gross Profit | $673.44M |
| Operating Expenses | $580.23M |
| Selling, General, and Administrative Expenses | $213.89M |
| Depreciation and Amortization | $1.68M |
| Research and Development | $105.00M |
| Other Operating Expenses | $260.40M |
| Operating Income/Loss | $93.22M |
| Income/Loss From Continuing Operations After Tax | $73.06M |
| Income/Loss From Continuing Operations Before Tax | $105.98M |
| Income Tax Expense/Benefit | $32.93M |
| Income Tax Expense/Benefit, Deferred | $14.53M |
| Net Income/Loss | $73.06M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $73.06M |
| Net Income/Loss Available To Common Stockholders, Basic | $73.06M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.98 |
| Diluted Earnings Per Share | $0.91 |
| Basic Average Shares | 225,265,145 |
| Diluted Average Shares | 241,338,845 |
| Assets | $825.28M |
| Current Assets | $594.17M |
| Inventory | $73.14M |
| Other Current Assets | $521.03M |
| Noncurrent Assets | $231.11M |
| Fixed Assets | $1.99M |
| Other Non-current Assets | $229.12M |
| Liabilities | $219.59M |
| Current Liabilities | $156.61M |
| Accounts Payable | $24.40M |
| Wages | $14.27M |
| Other Current Liabilities | $117.94M |
| Noncurrent Liabilities | $62.98M |
| Equity | $605.69M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $605.69M |
| Liabilities And Equity | $825.28M |
| Net Cash Flow From Operating Activities | $165.86M |
| Net Cash Flow From Operating Activities, Continuing | $165.86M |
| Net Cash Flow From Investing Activities | -$169.37M |
| Net Cash Flow From Investing Activities, Continuing | -$169.37M |
| Net Cash Flow From Financing Activities | $36.33M |
| Net Cash Flow From Financing Activities, Continuing | $36.33M |
| Net Cash Flow | $32.82M |
| Net Cash Flow, Continuing | $32.82M |
| Comprehensive Income/Loss | $72.45M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $72.56M |
| Other Comprehensive Income/Loss | $17.82M |
| Other Comprehensive Income/Loss Attributable To Parent | -$500.00K |